Claims
- 1. A motion platform for providing periodic acceleration to a living subject, comprising:
a box frame providing a foundation of the motion platform; a drive module adjoining said box frame, said drive module operably movable relative to said box frame; and a support connected to said drive module, said support comprising:
a planar surface for supporting the subject, said planar surface having a head end and a foot end; and a footboard connected at the foot end of the planar surface, said footboard rising perpendicularly to the planar surface and having cast shoes for securing the feet of the subject to the support; wherein said drive module provides periodic acceleration to the subject by moving in a line parallel to the planar surface of the support while the subject is secured to said support by said cast shoes on said footboard, and the periodic acceleration is alternately in the direction of the head end, and the foot end, of the planar surface, whereby the motion platform adds pulses to the fluid filled channels of the body of the subject.
- 2. The motion platform of claim 1, wherein the cast shoes are rigidly attached to the footboard with nuts and bolts.
- 3. The motion platform of claim 1, wherein the cast shoes are comprised of a solid material in the form of boots with a soft lining on the inside.
- 4. The motion platform of claim 3, wherein each of the solid boots are comprised of two parts, and wherein the parts are capable of being separated and then locked together so that the feet of the subject may be placed in the cast shoes and the secured within the cast shoes.
- 5. The motion platform of claim 1, wherein the cast shoes are comprised of pliable material, and wherein the feet of the subject are secured in the cast shoes by partially or wholly enclosing the feet with at least two portions of the pliable material and connecting the at least two portions of the pliable material with a fastening means.
- 6. The motion platform of claim 5, wherein the fastening means is at least one of a hook and loop connection, a buckle connection, and a notch and detent connection.
- 7. The motion platform of claim 1, wherein the drive module comprises:
four track wheels located substantially at the four corners of the upper portion of the drive module; wherein the drive module adjoins the box frame where the four track wheels of the drive module rest in four wheel tracks located on the upper portion of the box frame; and wherein the four wheels allow the head end-foot end motion of the drive module within the box frame, and the four wheel tracks limit said head end-foot end motion.
- 8. The motion platform of claim 5, wherein the fastening means is at least one of a hook and loop connection, a buckle connection, and a notch and detent connection.
- 9. The motion platform of claim 1, wherein the drive module comprises;
a frame to which the support is connected; at least one pair of rotating counterweights being attached to said frame by a drive shaft, wherein both counterweights in the at least one pair rotate around the drive shaft in the same plane.
- 10. The motion platform of claim 9, wherein the at least one pair of counterweights comprises;
a first counterweight attached by a first arm to the drive shaft; a second counterweight attached by a second arm to the drive shaft, wherein the second arm is longer than the first arm; wherein the mass of the counterweights is such that the centrifugal force exerted by the first counterweight is substantially the same as the centrifugal force exerted by the second counterweight when the counterweights are rotating around the drive shaft.
- 11. The motion platform of claim 9, wherein the first counterweight rotates clockwise in the rotation plane around the drive shaft, and the second counterweight rotates counter-clockwise in the rotation plane around the drive shaft, and
wherein a first point during rotation where the counterweights are aligned and a second point opposite from the first point during rotation where the counterweights are aligned are located such that a first line drawn from the drive shaft to the first point is in the direction of the head end and a second line drawn from the drive shaft to the second point is in the direction of the foot end; whereby the centrifugal forces of the counterweights during rotation cancel each other except in the direction of the foot end and the head end.
- 12. The motion platform of claim 11, wherein the at least one pair of counterweights comprises:
a head end pair of counterweights located toward the head end of the frame and comprising a head end drive shaft and first and second head end counterweights; a foot end pair of counterweights located toward the foot end of the frame and comprising a foot end drive shaft and first and second foot end counterweights.
- 13. The motion platform of claim 11, wherein the drive module further comprises:
a drive rotation motor for driving both the head end and foot end drive shafts; and a linear displacement motor for controlling a relative phase between the head end pair of counterweights and the foot end pair of counterweight, said relative phase being the timing relationship between when the front end counterweights align and when the head end counterweights align; wherein said drive rotation motor controls the speed of the movement of the support, and said linear displacement motor controls an amount of force applied in the head end and foot end directions.
- 14. The motion platform of claim 1, further comprising:
a mattress attached to the support for the subject to lie on.
- 15. The motion platform of claim 14, further comprising:
a bolster to be placed above the mattress in a location such that it supports and raises the buttocks region of a supine subject or the pubic region of a prone subject and the mattress supports either the upper back of the supine subject, or the upper chest of the prone subject.
- 16. The motion platform of claim 15, wherein the bolster is adjustable, thereby allowing an operator to control an amount the bolster raises the body of the subject.
- 17. The motion platform of claim 1, wherein the movement has a rate of substantially 100-200 Hz and a force in a range of about 0.09 to 0.35 g.
- 18. The motion platform of claim 1, wherein the provided periodic acceleration causes release of nitric oxide from the vascular endothelium of the subject through activation of endothelial nitric oxide synthase (eNOS) that in turn suppresses the transcriptional gene, nuclear factor kappa beta, thereby suppressing formation of inflammatory cytokines, tumor necrosis factor, adhesion molecules, inducible nitric oxide synthase (iNOS) activity, and endothelin-1 release.
- 19. The motion platform of claim 18, wherein the immunosuppressant effects are utilized to treat at least one of Alzheimer's disease, anaphylaxis, ankylosing spondylitis, asthma, atherosclerosis, chronic obstructive pulmonary disease, Crohn's disease, gout, Hashimoto's thyroiditis, ischemic-reperfusion injury (occlusive and embolic stroke attacks and myocardial infarction), multiple sclerosis, osteoarthritis, pemphigus, periodic fever syndrome, psoriasis, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosis, Type 1 diabetes mellitus, ulcerative colitis, vasculitides (Wegener's syndrome, Goodpasture's syndrome, giant cell arteritis, polyarteritis nodosa), xenograft rejection, bacterial dysentery, Chagas disease, cystic fibrosis pneumonia, filiarisis, heliobacter pylori gastritis, hepatitis C, influenza virus pneumonia, leprosy, neisseria or pneumococcal meningitis, post-streptococcal glomerulonephritis, sepsis syndrome, tuberculosis, bleomycin-induced pulmonary fibrosis, chronic allograft rejection, idiopathic pulmonary fibrosis, hepatic cirrhosis (post-viral or alcoholic), radiation-induced pulmonary fibrosis, schistosomiasis, peripheral vascular disease, coronary artery disease, angina pectoris, restenosis after relief of stenosis, arteriosclerotic plaque rupture, stroke, chronic venous insufficiency, cardiopulmonary bypass surgery, chronic heart failure, amyotrophic lateral sclerosis, myasthenia gravis, Huntington's chorea, Parkinson's disease, fibromyalgia, chronic fatigue syndrome, complex regional pain syndrome, muscular dystrophy, myopathy, obstructive sleep apnea syndrome, cerebral palsy, neuropathy, HIV dementia, head trauma/coma, atopic dermatitis, urticarias, pressure ulcers, burns, Behcet's disease, injuries, sprains, intervertebral disc disorder, sciatica, dislocations, fractures, carpal tunnel syndrome, the geriatric syndrome of frailty, endometriosis acute myeloblastic leukemia, melanoma, lung cancer, myelidysplastic syndrome, multiple myeloma, Kaposi's sarcoma in conjunction with HIV-1, Hodgkin's disease, cancer-related fatigue, hemolytic anemias such as sickle cell disease, hemolytic-uremic syndrome, and thalassemia have strong inflammatory components, depression, autism, and schizophrenia, allergic rhinitis, nasal and sinus polyps, and chronic sinusitis, smoking, chronic bronchitis, bronchiectasis, pneumoconiosis, adult respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), smoke burn inhalation injury to the lungs, inflammatory response due to overinflation of the lungs by mechanical ventilation, aseptic loosening of total hip replacement, aseptic necrosis of the hip, injury to donor organs due to brain death of the donor, periodontal disease, severe systemic inflammation with a vasodilatory syndrome after cardiopulmonary bypass for open heart surgery, repeated deep breathing of cold air, and cellulite.
- 20. The motion platform of claim 18, wherein the immunosuppressant effects are utilized to slow the ageing process.
- 21. The motion platform of claim 18, wherein the provided periodic acceleration provides better viability for donor organs intended for use in transplantation.
- 22. The motion platform of claim 18, wherein the provided periodic acceleration prevents the pulmonary inflammation associated with mechanical ventilation.
- 23. The motion platform of claim 18, wherein the provided periodic acceleration serves as treatment for Severe Acute Respiratory Syndrome (SARS).
- 24. The motion platform of claim 18, wherein the provided periodic acceleration serves as treatment for severe systemic inflammation with a vasodilatory syndrome after cardiopulmonary bypass, open-heart surgery.
- 25. The motion platform of claim 18, wherein treatment using the provided periodic acceleration replaces the use of corticosteroids and non-steroidal anti-inflammatory drugs (NSAID's) in management of inflammatory diseases.
- 26. The motion platform of claim 18, wherein the provided periodic acceleration provides cumulative effectiveness in treatment of inflammatory diseases.
- 27. The motion platform of claim 1, further comprising:
a processing means for determining the position of the dicrotic notch of the subject's pulse wave; and an override means for overriding the movement of the motion platform when the pulse is distorted by the pulses added by the periodic acceleration.
- 28. The motion platform of claim 1, further comprising:
a processing means for computing the a/b ratio for the dicrotic notch position; wherein the efficacy of the provided periodic acceleration in releasing nitric oxide into the circulation from upregulation of endothelial nitric oxide synthase (eNOS) may be measured.
- 29. The motion platform of claim 1, wherein the provided periodic acceleration administered once or twice daily serves as protection against inflammatory processes that occur episodically. such as asthma, exercising in cold air, prior to cardiopulmonary bypass surgery, allergic rhinitis, and mental stress.
- 30. The motion platform of claim 29, wherein the episodic inflammatory processes comprise asthma, exercising in cold air, the subject's condition prior to cardiopulmonary bypass surgery, allergic rhinitis, and mental stress.
- 31. The motion platform of claim 1, wherein the provided periodic acceleration is used to prevent failure of prosthetic hip replacements.
- 32. The motion platform of claim 1, wherein the provided periodic acceleration is used to treat cellulite.
- 33. The motion platform of claim 1, wherein the provided periodic acceleration serves as a means for at least one of preconditioning, conditioning and postconditioning tissues of the body to events that are associated with at least one of impaired blood supply and delivery of oxygen to the tissues
- 34. The motion platform of claim 33, wherein the provided periodic acceleration preconditions the heart, brain, kidneys, lungs, gastrointestinal tract, liver and pancreas in patients when administered prior to cardiopulmonary bypass surgery.
- 35. The motion platform of claim 33, wherein the provided periodic acceleration preconditions the heart, brain, kidneys, lungs, gastrointestinal tract, liver and pancreas during ascent to high altitude.
- 36. The motion platform of claim 33, wherein the provided periodic acceleration preconditions the lungs of the subject for a case of deep venous thrombosis.
- 37. The motion platform of claim 33, wherein the provided periodic acceleration preconditions the heart, brain, kidneys, lungs, gastrointestinal tract, liver and pancreas in a subject who has atrial fibrillation/flutter and in whom cardioversion is indicated.
- 38. The motion platform of claim 33, wherein the provided periodical acceleration conditions at least one of:
the heart during cardiopulmonary resuscitation, acute myocardial infarction, and unstabile angina; the brain during an acute stroke; the lungs during pulmonary embolism/thrombosis; the brain, kidneys, gastrointestinal tract, liver and pancreas during an arterial embolism; and the heart, brain, kidneys, lungs, gastrointestinal tract, liver and pancreas during sepsis, shock and hypotension states.
- 39. The motion platform of claim 33, wherein the provided periodical acceleration postconditions at least one of:
the brain after an acute stroke; the lungs after pulmonary embolism/thrombosis; the heart, brain, kidneys, lungs, gastrointestinal tract, liver and pancreas while the subject is recovering from sepsis, shock, and hypotension states; the heart, brain, kidneys, lungs, gastrointestinal tract, liver and pancreas while the subject is at a high altitude; and the heart, brain, kidneys, lungs, gastrointestinal tract, liver, pancreas, and skeletal muscles before the subject engages in physical activity in order to enhance physical performance.
- 40. The motion platform of claim 15, wherein the provided periodic acceleration permits efficient, non-invasive ventilation because the subject's rib cage and abdomen move in phase.
- 41. The motion platform of claim 40, wherein the non-invasive ventilation is utilized in clinical situations where conventional positive and negative pressure mechanical ventilators are indicated.
- 42. The motion platform of claim 40, wherein the non-invasive ventilation is utilized in conjunction with conventional positive and negative pressure mechanical ventilators.
- 43. The motion platform of claim 40, wherein the non-invasive ventilation is utilized in patients requiring non-invasive nocturnal ventilation.
- 44. The motion platform of claim 40, wherein the non-invasive ventilation is utilized in patients who have the obstructive sleep or central sleep apneas to reduce the prevalence of apneas.
- 45. The motion platform of claim 40, wherein the non-invasive ventilation is utilized to cause release of beneficial mediators such as nitric oxide from vascular endothelium into the circulation.
- 46. The motion platform of claim 40, wherein the non-invasive ventilation replaces a mechanical ventilator, thereby protecting the subject from mechanical ventilator induced lung injury by inducing the production of nitric oxide, which, in turn, suppresses nuclear factor kappa beta which is related to mechanical ventilator induced lung injury.
- 47. The motion platform of claim 40, wherein the non-invasive ventilation is utilized to aid in the removal of retained bronchopulmonary secretions in a ventilator-dependent subject.
- 48. The motion platform of claim 47, wherein the ventilator-dependent subject is trained to relax with an opened glottis, thereby aiding in removal of the retained bronchopulmonary secretions.
- 49. The motion platform of claim 1, wherein the provided periodic acceleration causes release of nitric oxide from the vascular endothelium through activation of endothelial nitric oxide synthase (eNOS) that in turn scavenges reactive oxygen species thereby diminishing or eliminating oxidative stress.
- 50. The motion platform of claim 49, wherein the release of small quantities of nitric oxide from endothelial nitric oxide synthase causes antioxidant activity which treats and prevents the diseases and conditions that have oxidative stress as a major component.
- 51. The motion platform of claim 50, wherein the diseases and conditions that have oxidative stress as a major component comprise one of: smoking, environmental pollution, cystic fibrosis, asthma, Alzheimer's disease, Parkinson's disease, supranuclear palsy, amyotrophic lateral sclerosis, motor neuron disease, HIV dementia, Huntington's chorea, Friedrich's ataxia, stroke, obstructive sleep apnea syndrome, cognitive impairment in the elderly, muscular dystrophy, reflux esophagitis, Helicobacter pylori infection, inflammatory bowel disease, alchoholic liver disease, atherosclerosis, hypertension, chronic heart failure, chronic renal failure, diabetes mellitus, dyslipidemias, hyperhomocystinuria, restenosis of coronary vessels, ischemia-perfusion injury, endothelial dysfunction, endometriosis, vein graft failure, cardiopulmonary bypass surgery, ionizing radiation, atopic dermitis, contact dermatitis, psoriasis, and rheumatoid arthritis.
- 52. The motion platform of claim 50, wherein the release of nitric oxide from endothelial nitric oxide synthase cause antioxidant activity which slows the ageing process
- 53. The motion platform of claim 51, wherein the periodic acceleration is administered prior to exposure to oxidative stress from environmental sources in order to prevent deleterious effects.
- 54. The motion platform of claim 53, wherein the environmental sources causing oxidative stress comprise at least one of hyperbaric oxygen treatments, hard-hat diving, and excessive atmospheric ozone.
- 55. The motion platform of claim 17, wherein the movement has a rate of substantially 120-180 Hz and a force in a range of about 0.2 to 0.25 g.
- 56. The motion platform of claim 55, wherein the periodic acceleration is provided at a rate of about 120 Hz with a force of about 0.15 g. in order to provide as gentle a treatment as possible while still having a therapeutic effect.
- 57. A motion platform for providing periodic acceleration to an animal, comprising:
a box frame providing a foundation of the motion platform; a drive module adjoining said box frame, said drive module operably movable relative to said box frame; and a support connected to said drive module, said support comprising a sling for supporting the animal, said sling positioned under the torso of the animal such that the head of the animal is on one side of said sling and the rear of the animal is on the other side of said sling; wherein said drive module provides periodic acceleration to the animal by moving in a line perpendicular to said sling while the animal is held in said sling, and the periodic acceleration is alternately in the direction of the head, and the rear, of the animal, whereby the motion platform adds pulses to the fluid filled channels of the body of the animal.
- 58. The motion platform of claim 57, wherein the animal is a horse.
- 59. The motion platform of claim 58, wherein the provided periodic acceleration serves as a treatment for osteoarthritis, colic, heaves, and chronic obstructive pulmonary disease.
- 60. The motion platform of claim 58, wherein the provided periodic acceleration preconditions the gastrointestinal tract of the horse to the ischemic effects of colic.
- 61. The motion platform of claim 58, wherein the provided periodic acceleration suppresses the inflammatory response found in association with colic.
- 62. The motion platform of claim 58, wherein the provided periodic acceleration preconditions the gastrointestinal tract of the horse to the ischemic effects of colic.
- 63. The motion platform of claim 58, wherein the provided periodic acceleration prevents worsening of exercise-induced pulmonary hemorrhage in the horse once it has occurred.
- 64. The motion platform of claim 58, wherein the periodic acceleration provided prior to exercise ameliorates exercise-induced pulmonary hemorrhage in the horse.
- 65. The motion platform of claim 58, wherein the periodic acceleration is provided prior to a race or training in order to precondition the heart, brain, kidneys, lungs, gastrointestinal tract, liver, pancreas, and skeletal muscles of the horse to provide better athletic performance.
- 66. A motion platform for providing periodic acceleration to a living subject, comprising:
a box frame providing a foundation of the motion platform, said box frame having four wheel tracks located substantially at the four corners of the top portion of the box frame; a drive module having four track wheels located substantially at the four corners of the top portion of the drive module, wherein said track wheels extend from the top portion of the drive module and rest in the wheel tracks of the box frame, whereby the drive module sits within the box frame and is operably movable relative to said box frame, and wherein the drive module comprises:
a frame with a head end and a foot end; a head end pair of counterweights located toward the head end of the frame and attached to the frame by a head end drive shaft around which rotate first and second head end counterweights which share a first plane of rotation, wherein the first head end counterweight rotates in an opposite direction of the second head end counterweight such that their centrifugal forces cancel each other except in the direction of the head end and the foot end; a foot end pair of counterweights located toward the foot end of the frame and attached to the frame by a foot end drive shaft around which rotate first and second foot end counterweights which share a second plane of rotation, wherein the first foot end counterweight rotates in an opposite direction of the second foot end counterweight such that their centrifugal forces cancel each other except in the direction of the head end and the foot end; wherein the first plane of rotation is the same as the second plane of rotation; wherein the centrifugal forces and a support connected to said drive module, said support comprising:
a planar surface for supporting the subject, said planar surface having a head end connected to the head end of the frame of the drive module, and a foot end connected to the foot end of the frame of the drive module; and a footboard connected at the foot end of the planar surface, said footboard rising perpendicularly to the planar surface and having cast shoes for securing the feet of the subject to the support; wherein said drive module provides periodic acceleration to the subject by moving in a line parallel to the planar surface of the support while the subject is secured to said support by said cast shoes on said footboard, and the periodic acceleration is alternately in the direction of the head end, and the foot end, of the planar surface, whereby the motion platform adds pulses to the fluid filled channels of the body of the subject.
RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Patent Application Serial No. 60/380,790 which was filed on May 15, 2002 and is hereby incorporated in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60380790 |
May 2002 |
US |